Prosecution Insights
Last updated: October 23, 2026
Application No. 18/560,675

FOLATE RECEPTOR-TARGETED CONJUGATES WITH BRUSH BORDER MEMBRANE ENZYME-CLEAVABLE LINKERS AND METHODS OF USE IN IMAGING AND TREATING CANCER

Non-Final OA §102§Other
Filed
Nov 13, 2023
Priority
May 14, 2021 — provisional 63/188,910 +2 more
Examiner
ROGERS, JAMES WILLIAM
Art Unit
1618
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Purdue Research Foundation
OA Round
1 (Non-Final)
46%
Grant Probability
Moderate
1-2
OA Rounds
11m
Est. Remaining
68%
With Interview

Examiner Intelligence

Grants 46% of resolved cases
46%
Career Allowance Rate
418 granted / 906 resolved
-13.9% vs TC avg
Strong +22% interview lift
Without
With
+22.4%
Interview Lift
resolved cases with interview
Typical timeline
3y 10m
Avg Prosecution
47 currently pending
Career history
965
Total Applications
across all art units

Statute-Specific Performance

§101
0.7%
-39.3% vs TC avg
§103
42.5%
+2.5% vs TC avg
§102
22.2%
-17.8% vs TC avg
§112
23.9%
-16.1% vs TC avg
Black line = Tech Center average estimate • Based on career data from 906 resolved cases

Office Action

§102 §Other
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Election/Restrictions Applicant’s election without traverse of group I and the species of BBM4 in the reply filed on 8/7/2026 is acknowledged. Applicants’ election of species of BBM4 is free of the prior art. As a result the search has been extended to a compound of formula I where FRTL is F3 as shown in claim 15, BBMecL is Asp-X as recited in claim 17 and AA is any dye from claim 19. If prior art is then found that anticipates or renders obvious the Markush-type claim with respect to a nonelected species, the Markush-type claim shall be rejected and claims to the nonelected species held withdrawn from further consideration. The prior art search, however, will not be extended unnecessarily to cover all nonelected species. Should applicant, in response to this rejection of the Markush-type claim, overcome the rejection, as by amending the Markush-type claim to exclude the species anticipated or rendered obvious by the prior art, the amended Markush-type claim will be reexamined. The ** > examination < will be extended to the extent necessary to determine patentability of the Markush-type claim. In the event prior art is found during the reexamination that anticipates or renders obvious the amended Markush-type claim, the claim will be rejected and the action can be made final unless the examiner introduces a new ground of rejection that is neither necessitated by applicant' s amendment of the claims nor based on information submitted in an information disclosure statement filed during the period set forth in 37 CFR 1.97(c) with the fee set forth in 37 CFR 1.17(p). See MPEP § 706.07(a). Amendments submitted after the final rejection further restricting the scope of the claim may be denied entry if they do not comply with the requirements of 37 CFR 1.116. See MPEP § 714.13. See MPEP 803.02. Claims 2-3,5,7-8,15-17 (elected structure does not read on claim 2),21-23,25 (imaging agent elected) and 27-41 are withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected species or invention, there being no allowable generic or linking claim. Claim Rejections - 35 USC § 102 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. Claim(s) 1,18-19 is/are rejected under 35 U.S.C. 102a1 as being anticipated by Low et al. (US 2015/0023874 A1), cited IDS. Low discloses folate receptor binding ligands conjugated to imaging agents including rhodamine (meeting AA of claim 19) through linkages that include amino acids which include Asp-Cys, reading on the claimed BBMecLAsp-X in claim 17. See entire disclosure, especially abstract, [0043]-[0082],[0084], scheme 2 at [0238] and claims. Specific structures included the following conjugate in Scheme 2: PNG media_image1.png 168 586 media_image1.png Greyscale , featuring Asp-Cys bond, where R is an imaging agent. Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to JAMES W ROGERS whose telephone number is (571)272-7838. The examiner can normally be reached 9:30-6:00 PM. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Michael Hartley can be reached at 571-272-0616. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /JAMES W ROGERS/ Primary Examiner, Art Unit 1618
Read full office action

Prosecution Timeline

Nov 13, 2023
Application Filed
Sep 29, 2026
Non-Final Rejection mailed — §102, §Other (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12759047
Metal-based core nanoparticles, synthesis and use
4y 3m to grant Granted Oct 13, 2026
Patent 12758636
POLYTETRAFLUOROETHYLENE CO-POLYMER EMULSIONS
3y 6m to grant Granted Oct 13, 2026
Patent 12758658
DOUBLE-COMPONENT GASTRIC ULTRASOUND EXAMINATION AIDED DEVELOPER AND PREPARATION METHOD THEREFOR
2y 10m to grant Granted Oct 13, 2026
Patent 12741033
NOOTROPIC FULLERENES AND USE
4y 7m to grant Granted Sep 22, 2026
Patent 12708603
NOVEL TREATMENT APPROACH BY TARGETED DELIVERY OF BIOACTIVE MOLECULES BIO MODULATED CERAMICS
5y 10m to grant Granted Aug 18, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
46%
Grant Probability
68%
With Interview (+22.4%)
3y 10m (~11m remaining)
Median Time to Grant
Low
PTA Risk
Based on 906 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month